|Bid||0.0500 x N/A|
|Ask||0.0550 x N/A|
|Day's Range||0.0550 - 0.0600|
|52 Week Range||0.0250 - 0.0800|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2023 - Nov 13, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
HALIFAX, Nova Scotia, September 27, 2023--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual meeting of shareholders held earlier today.
HALIFAX, Nova Scotia, September 27, 2023--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, and key members of Appili’s scientific team, will participate at the 10th International Tularemia Conference, from September 24 to 26, 2023. Dr. Gelhaus will present an update on Appili’s biodefense vaccin
The U.S. Food and Drug Administration (FDA) on Monday approved Canadian drugmaker Appili Therapeutics' liquid oral form of antibiotic drug metronidazole, offering an alternative to patients who have difficulty taking injections or pills. An injectable form of the drug, which is commonly used in the treatment of bacterial and parasitic infections, has been in shortage in the United States since early last year due to high demand and regulatory delays. Appili said its partner, privately-held Saptalis, will sell the newly approved form of the drug under the brand name Likmez in the United States.